With patents expiring shortly on numerous branded prescriptions,
pharmaceutical manufacturers are expected to lose up to $180 billion
in the U.S. in sales to generics over the next five years.
But a type of generic drug, if positioned carefully to the right market,
could offer a new way for pharmaceutical manufacturers to actually
broaden their sales.

Called “branded generics”, they are generic drugs that carry a big
pharma name and are gaining increasing popularity in emerging markets—especially China, India, and Latin
America. Generic drugs already represent 25 percent on average of worldwide pharmaceuticals sales. Thanks
to these markets, branded generics are likely to reach up to 75 percent of sales growth within the next 10 years.

That’s because overseas consumers respect and trust branded drugs more than local generics. Consumers
perceive the latter as being satisfied with lax quality controls, while branded drugs are trusted to have a higher
level of quality and effectiveness.

With the tremendous growth in sales in emerging markets expected over the next 10 years, now is the time to
join the BRANDED GENERICS conference to find out whether this opportunity for sales expansion is right for you.
You will meet face-to-face with hundreds of pharmaceutical and generic manufacturers from the U.S. and
overseas, and walk away with valuable insights and contacts for your next campaign!